Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 3
1954 3
1955 3
1957 3
1958 2
1959 2
1960 4
1961 4
1962 5
1963 4
1964 7
1965 4
1966 2
1967 1
1968 4
1969 8
1970 7
1971 7
1972 6
1973 9
1974 6
1975 8
1976 8
1977 9
1978 9
1979 3
1980 8
1981 7
1982 7
1983 10
1984 7
1985 4
1986 6
1987 5
1988 6
1989 9
1990 6
1991 6
1992 4
1993 7
1994 10
1995 4
1996 1
1997 11
1998 8
1999 5
2000 6
2001 8
2002 4
2003 12
2004 10
2005 18
2006 14
2007 13
2008 13
2009 18
2010 24
2011 30
2012 42
2013 40
2014 43
2015 68
2016 68
2017 67
2018 66
2019 81
2020 105
2021 112
2022 130
2023 121
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

1,294 results

Results by year

Citations

21 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Did you mean do cancer (5,114,045 results)?
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. ...The …
BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and …
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma.
Johnson P, Zhou Q, Dao DY, Lo YMD. Johnson P, et al. Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):670-681. doi: 10.1038/s41575-022-00620-y. Epub 2022 Jun 8. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35676420 Review.
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-related death worldwide. The treatment of HCC remains challenging and is largely predicated on early diagnosis. ...The second is to use circulating nucleic acid biomarkers, which includ …
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-related death worldwide. The treatment of HCC …
Immune organoids: from tumor modeling to precision oncology.
Dao V, Yuki K, Lo YH, Nakano M, Kuo CJ. Dao V, et al. Trends Cancer. 2022 Oct;8(10):870-880. doi: 10.1016/j.trecan.2022.06.001. Epub 2022 Jun 27. Trends Cancer. 2022. PMID: 35773148 Free PMC article. Review.
Cancer immunotherapies, particularly immune checkpoint inhibitors, are rapidly becoming standard-of-care for many cancers. ...
Cancer immunotherapies, particularly immune checkpoint inhibitors, are rapidly becoming standard-of-care for many cancers. ...
Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Bui TO, Dao VT, Nguyen VT, Feugeas JP, Pamoukdjian F, Bousquet G. Bui TO, et al. Eur Urol. 2022 Apr;81(4):349-361. doi: 10.1016/j.eururo.2021.12.010. Epub 2022 Jan 3. Eur Urol. 2022. PMID: 34991918 Review.
EVIDENCE ACQUISITION: Articles were selected from Medline and Embase libraries using the search algorithm ("Kidney Neoplasms"[Mesh] OR "Renal Cell Carcinoma") AND ("Genomics"[Mesh] OR "Mutation") from January 1999 to February 2021. ...PATIENT SUMMARY: We reviewed the liter …
EVIDENCE ACQUISITION: Articles were selected from Medline and Embase libraries using the search algorithm ("Kidney Neoplasms"[Mesh] O …
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.
Dao V, Heestand G. Dao V, et al. Curr Probl Cancer. 2023 Aug;47(4):100960. doi: 10.1016/j.currproblcancer.2023.100960. Epub 2023 May 10. Curr Probl Cancer. 2023. PMID: 37285606 Review.
The addition of antiepidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab or panitumumab, to conventional chemotherapy has improved clinical outcomes for rat sarcoma virus (RAS) wild-type advanced colorectal cancer patients, however, durable responses an …
The addition of antiepidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab or panitumumab, to conventional chemotherapy ha …
Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application.
Zhang L, Xu X, Su X. Zhang L, et al. Mol Cancer. 2020 Mar 2;19(1):48. doi: 10.1186/s12943-020-01154-0. Mol Cancer. 2020. PMID: 32122338 Free PMC article. Review.
With the better understanding of cancer-associated immune cells, especially T cells, immunotherapy was developed and applied in multiple cancers and exhibits remarkable efficacy. ...In this review, we summarize the functions and regulatory mechanisms of ncRNAs in …
With the better understanding of cancer-associated immune cells, especially T cells, immunotherapy was developed and applied in multi …
Response.
Ait Ouakrim D, Dashti SG, Win AK. Ait Ouakrim D, et al. J Natl Cancer Inst. 2015 Dec 27;108(2):djv385. doi: 10.1093/jnci/djv385. Print 2016 Feb. J Natl Cancer Inst. 2015. PMID: 26711871 Free PMC article. No abstract available.
BI-RADS 5: More than Cancer.
Dao KA, Rives AF, Quintana LM, Kritselis MA, Fishman MDC, Sarangi R, Slanetz PJ. Dao KA, et al. Radiographics. 2020 Sep-Oct;40(5):1203-1204. doi: 10.1148/rg.2020200054. Radiographics. 2020. PMID: 32870767 No abstract available.
Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition.
Yazal T, Bailleul J, Ruan Y, Sung D, Chu FI, Palomera D, Dao A, Sehgal A, Gurunathan V, Aryan L, Eghbali M, Vlashi E. Yazal T, et al. Mol Cancer Ther. 2022 Jan;21(1):79-88. doi: 10.1158/1535-7163.MCT-20-1103. Epub 2021 Nov 1. Mol Cancer Ther. 2022. PMID: 34725193
When combined with radiotherapy, EAD1 is consistently superior to HCQ not only as a single agent, but also in radiosensitizing PDAC cells, and perhaps most importantly, in decreasing the self-renewal capacity of PDAC cancer stem cells (PCSC). The more pronounced sensitizin …
When combined with radiotherapy, EAD1 is consistently superior to HCQ not only as a single agent, but also in radiosensitizing PDAC cells, a …
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, Kyi C, O'Cearbhaill RE, Liu C, Dao T, Scheinberg DA. Mun SS, et al. Cancer Immunol Immunother. 2023 Nov;72(11):3773-3786. doi: 10.1007/s00262-023-03529-w. Epub 2023 Aug 27. Cancer Immunol Immunother. 2023. PMID: 37635172 Free PMC article.
Epithelial ovarian cancer is the most lethal of gynecological cancers. The therapeutic efficacy of chimeric antigen receptor (CAR) T cell directed against single antigens is limited by the heterogeneous target antigen expression in epithelial ovarian tumors. ...Dual …
Epithelial ovarian cancer is the most lethal of gynecological cancers. The therapeutic efficacy of chimeric antigen receptor ( …
1,294 results